Anthem Biosciences IPO GMP, Key Details, Price, Dates, and Allotment Status

Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organisation (CRDMO) services. It is Bengaluru-based company that came up with its Initial Public Offering (IPO) on July 14, 2025, they aims to raise ₹3,395 crores through an Offer for Sale (OFS) of 5.96 crore worth of equity shares. 

In this article, we have covered the essential details of the Anthem Biosciences IPO, including its Grey Market Premium (GMP), price band, key dates, allotment process, and more.

Anthem Biosciences IPO Details

• Issue Type: Book-Built Issue (Mainboard IPO)
• Total Issue Size: ₹3,395 crores (5,95,61,404 equity shares)
• Offer Type: 100% Offer for Sale (OFS), no fresh issue
• Face Value: ₹2 per equity share
• Price Band: ₹540 to ₹570 per share
• Lot Size: 26 shares
• Minimum Investment (Retail): ₹14,040 (1 lot, 26 shares at ₹540)
• Minimum Investment at Cut-off (Retail): ₹14,820 (1 lot, 26 shares at ₹570)
• Minimum Investment (sHNI): ₹2,07,480 (14 lots, 364 shares at ₹570)
• Minimum Investment (bHNI): ₹10,07,760 (68 lots, 1,768 shares at ₹570)
• Employee Reservation: Equity shares aggregating up to ₹8.25 crores
• IPO Reservation:
  • Qualified Institutional Buyers (QIB): 50%
  • Non-Institutional Investors (NII/HNI): 15%
  • Retail Investors: 35%
• Listing Exchanges: IPo was listing on Both the Exchanges BSE and NSE
• Book-Running Lead Managers: JM Financial Limited, Citigroup Global Markets India, J.P. Morgan India, Nomura Financial Advisory and Securities (India) Pvt Ltd are appointed as a book running managers for the IPO.
• Registrar: KFin Technologies Limited

Anthem Biosciences IPO Timeline

About Anthem Biosciences Limited

Anthem Biosciences Limited was established in 2006, it is a technology-driven CRDMO which was based in Bengaluru, India. The company provides end-to-end services across 

1. Drug discovery
2. Drug Development
3. Drug manufacturing
4. Specialising in New Chemical Entities (NCEs) and New Biological Entities (NBEs). 

Anthem serves over 425 customers in 44+ countries, including the U.S., Europe, and Japan. It caters to emerging biotech firms and global pharmaceutical giants.

Key Business Highlights

• Service Portfolio: Anthem excels in producing fermentation-based Active Pharmaceutical Ingredients (APIs) like probiotics, enzymes, peptides, vitamin analogues, and biosimilars. It supports the entire drug lifecycle, from discovery to commercialisation.
• Global Reach: Operates in 44+ countries with a client base of over 425, including major pharmaceutical companies.
• Infrastructure: Operates two cGMP-compliant facilities with a fermentation capacity of 142 kL (expanding to 182 kL), the largest among Indian CRDMOs.
• R&D and Innovation: Manages 196 ongoing projects and holds 8 granted patents (1 in India, 7 overseas) with 24 pending applications.
• Promoters: Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj.

Strategic Objectives

• OFS Funds: The IPO is totally an Offer for Sale, with all funds going directly to the shareholders after deducting offer-related expenses.
• Listing Benefits: After this IPO, the company aims to enhance visibility and liquidity by listing on exchanges like NSE & BSE.
• Company Expansion plans: Anthem Biosciences has some plans to invest some funds in a greenfield facility under its subsidiary called “Neoanthem”, which is going to start its operations before the 3rd quarter of FY2025.

Anthem Biosciences Financial Details

Anthem Biosciences has shown robust financial growth over the years, positioning it as a leader in the CRDMO space. Below are in-depth financial metrics:

Key Financial Metrics

• Market Capitalisation: The company’s Market Cap will be ₹31,867 Cr at the upper price band of ₹570.
• Revenue Growth: Anthem has grown by 30% YoY from ₹1,483.07 Cr in FY24 to ₹1,930.29 Cr in FY25.
• PAT Growth: PAT growth has increased to 23% YoY from ₹367.31 Cr in FY24 to ₹451.26 Cr in FY25.
• P/E Ratio: P/E ratio of Anthem Biosciences stands at 70.9x which is based on FY25 earnings.
• EV/EBITDA: 45x of EBITDA as per the FY25 earnings.
• Promoter Holding Post-IPO: 74.69% (down from 76.88%).

Anthem Biosciences IPO GMP (Grey Market Premium)

The GMP(Grey Market Premium) for Anthem Biosciences IPO 14 July is reported at ₹100, which suggests an expected listing price of ₹570(with 17.54% premium over the upper price band of ₹570) if the GMP continues. The GMP has fluctuated over the past days as follows:

Things to Consider Before Applying Anthem Biosciences IPO?

Before applying for the IPO, one should consider the following details of the company like its strengths and risks to understand the potential of the Company.

Strengths

• Industry Leadership: Anthem is among the few Indian CRDMOs with integrated NCE and NBE capabilities, serving a diverse global clientele.
• Strong Financials: 30% revenue growth and 23% PAT growth from FY24 to FY25, with healthy margins and robust credit metrics.
• Global Presence: Serves 425+ clients across 44+ countries, with a focus on high-growth markets like probiotics and biosimilars.
• Regulatory Compliance: Facilities approved by USFDA, PMDA (Japan), and EU QPs, ensuring global standards.
• Future-Ready Portfolio: Expertise in emerging areas like RNA therapeutics, ADCs, and oligonucleotides.

Risks

• No Proceeds to Company: The entire IPO is a 100% OFS, the company receives no funds hence the promotors are exiting the orgainsation.
• High Valuation: Anthem Pharma was having a high P/E ratio of 70.9 which is very higher than its peers within the CRDMOs industry, potentially signaling the price is overvalued.
• Regulatory Risks: Delays or failures in regulatory approvals could impact operations.
• Operational Risks: The company was handling hazardous materials which poses risks of accidents, which could impact the company’s operations.
• Market Competition: Faces competition from established players like Syngene International and Divi’s Laboratories.

How to Apply for Anthem Biosciences IPO?

Investors can apply for Anthem Biosciences IPO through the below methods:

• Online ASBA: Use your bank’s net banking platform to apply via ASBA.
• UPI: Apply through UPI using a registered broker or trading app
• Offline: If you want to proceed in the offline manner you need to submit a physical application form through your stockbroker.

How to Apply for Anthem Biosciences IPO Online via ASBA

• Log in to your bank’s net banking portal.
• Navigate to the IPO section
• select “Anthem Biosciences IPO” from the dropdown.
• Enter the lot size price 
• Click on the submit option.
• Confirm the application via bank authorisation.

How to Apply for Anthem Biosciences IPO via UPI

• Go to your stockbroker app or website.
• Head to the IPO section
• Select “Anthem Biosciences IPO” in the IPO section.
• Input your UPI ID, lot size, and price.
• Confirm the UPI mandate before July 16, 2025 5:00 PM

How to Apply for Anthem Biosciences IPO via Offline Application:

• Download the IPO form from the BSE/NSE website.
• Fill in the details of your DP details and Bank Details and lot size including the Bid Price.
• Submit it to your stockbroker.

Anthem Biosciences IPO Allotment Status

The IPO allotment status will be available on July 17, 2025. You can check the allotment results in the registrar's (Kfin tech) website by using the Application Number, Pan number or DP ID by following the steps mentioned below,

• Visit the Kfin tech website.
• Select “HDB Financial Services Limited” from the dropdown menu.
• Enter your PAN, application number, or DP/Client ID.
• Click “Search” to view your allotment status.

and NSE & BSE portals, and alternatively, you can check the status on the broker's website or app where you have applied for the IPO 

Anthem Biosciences IPO Contact Details

If you need more details of the IPO, you can check the company’s official press releases, or you can reach the company or the registrar at the given details.

Anthem Biosciences Limited:

• Address: No. 49, F1 & F2, Canara Bank Road, 
  Bommasandra Industrial Area, Phase 1, 
  Bommasandra, Bengaluru, 
  Karnataka, 560099.
• Contact NO: +91 0806672400
• Email ID: investors.abl@anthembio.com

Registrar:

• Name: Kfin Technologies Limited
• Address: Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad, Telangana, 500032
• Contact NO: +91 40 6716 2222
• Email id: anthem.ipo@kfintech.com

Conclusion

Anthem Biosciences IPO is an opportunity to invest in their company, which was an innovation-driven CRDMO having strong financial performance in probiotics, biosimilars, and advanced therapeutics, coupled with a robust client base.

However, the high P/E ratio and lack of fresh issue proceeds warrant caution. Investors should weigh the company’s fundamentals, market sentiment, and GMP trends before applying.

Disclaimer: This article is only for informational purposes only should not be taken as an investment advice please consult SEBI-registered financial advisors and review the Red Herring Prospectus (RHP) before investing. IPO investments carry market risks, and decisions should be based on thorough research.

Related Articles:
1. Accretion Pharmaceuticals IPO - Check Issue Date, Price, GMP, Allotment Status
2. Scoda Tubes IPO - Check Issue Date, Price, GMP, Allotment Status
3. Oswal Pumps IPO GMP, Date, Price, Allotment Status
4. Globe Civil IPO GMP, Date, Price, Allotment Status
5. HDB Financial Services IPO GMP, Price, Date, Allotment Status
6. Cryogenic OGS IPO GMP, Price, Date, Allotment Status
7. GLEN Industries IPO GMP, Price, Date, Allotment Status